Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.

@article{Bloom2005MulticenterST,
  title={Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.},
  author={Barry T. Bloom and Robert L. Schelonka and Tom J Kueser and Whit Walker and Elizabeth Jung and David H Kaufman and Karen Kesler and Destrey Roberson and Joseph M. Patti and Seth Hetherington},
  journal={The Pediatric infectious disease journal},
  year={2005},
  volume={24 10},
  pages={858-66}
}
BACKGROUND Prophylactic administration of intravenous immunoglobulin has been inconsistent in reducing the risk of sepsis in very low birth weight (VLBW) infants presumably because of varying titers of organism specific IgG antibodies. INH-A21 is an intravenous immunoglobulin from donors with high titers of antistaphylococcal antibodies. This dose-ranging study explored safety and preliminary activity of INH-A21 for prevention of staphylococcal sepsis in VLBW infants. METHODS This was a… CONTINUE READING